A 24-month, phase I/II dose ranging clinical trial to evaluate the safety and efficacy of Bimatoprost Sustained Release Implant in lowering IOP in patients with open angle glaucoma and ocular hypertension

Trial Profile

A 24-month, phase I/II dose ranging clinical trial to evaluate the safety and efficacy of Bimatoprost Sustained Release Implant in lowering IOP in patients with open angle glaucoma and ocular hypertension

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Bimatoprost (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 01 Mar 2017 New source identified and integrated (ClinicalTrials.gov; NCT01157364)
    • 04 May 2016 According to an Allergan media release, safety and efficacy data through month 6, from this trial will be presented during the 2016 American Society of Cataract and Refractive Surgery (ASCRS) Symposium & Congress.
    • 19 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top